Immune Modulation With PRaG-1 Treatment

Summary

The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.

Timeline

Start

2025-06-15

Primary completion

2026-05-26

Completion

2026-06-26

Drugs

Indications